SCHEMBL8246317

SCHEMBL8246317

COc1ccc(CN2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](O)CN3C2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.46
▸ CTSS P25774 1/20 0.41
▸ ALOX15 P16050 1/20 0.32
▸ MMP1 P03956 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ MGAT2 Q10469 2/20 0.32
▸ CYP3A4 P08684 3/20 0.32
▸ ADRB3 P13945 1/20 0.31
▸ ADRA2B P18089 1/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ HDAC1 Q13547 3/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ HDAC6 Q9UBN7 2/20 0.30
▸ HDAC3 O15379 1/20 0.30
▸ HDAC4 P56524 1/20 0.30
▸ HDAC7 Q8WUI4 1/20 0.30
▸ HDAC2 Q92769 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13502757 0.90 CTSB (0.47) CTSBCTSSALOX15MMP1MMP13
SCHEMBL15159925 0.90 CYP3A4 (0.38) CTSBCTSSALOX15MMP1MMP13
SCHEMBL13502623 0.89 CTSB (0.45) CTSBCTSSCYP3A4ADRB3ADRA2B
SCHEMBL13502620 0.88 CTSB (0.45) CTSBCTSSCYP3A4ADRB3ADRA2B
SCHEMBL16628773 0.88 ADRB3 (0.36) CTSBALOX15MMP1MMP13CYP3A4
SCHEMBL16628772 0.88 ADRB3 (0.36) CTSBALOX15MMP1MMP13CYP3A4
SCHEMBL3523171 0.88 MMP1 (0.34) CTSBALOX15MMP1MMP13CYP3A4
SCHEMBL10156974 0.86 ALDH1A1 (0.36) CTSBALOX15MMP1MMP13ADRB3
SCHEMBL995888 0.86 ALDH1A1 (0.36) CTSBALOX15MMP1MMP13ADRB3
SCHEMBL8239738 0.86 ALDH1A1 (0.36) CTSBALOX15MMP1MMP13ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919898-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARM LTD (IE) 2011-01-26 — — EP disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed
WO-2007014922-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 CTSB 3457/4885CTSS 2129/4885ALOX15 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback